Datapoint: Rexulti Scores First FDA Nod for Alzheimer’s Agitation
The FDA on May 10 approved Otsuka and Lundbeck’s Rexulti for the treatment of agitation associated with dementia due to Alzheimer’s disease, making it the first and only therapy available for that indication. Agitation is one of the “most complex and stressful aspects of caring for people” with Alzheimer’s dementia, and occurs in about 50% of patients, Otsuka noted in a press release. The second-generation oral antipsychotic was first approved to treat major depressive disorder and schizophrenia in 2015. For those indications, Rexulti currently holds covered or better status for 92% of all insured lives under the pharmacy benefit. Coverage requires prior authorization and/or step therapy for about 43% of insured lives.
SOURCE: MMIT Analytics, as of 5/15/23
